RSFNet: A retention-based network with spatial-frequency joint enhancement for infrared small target detection.

Depression has serious implications for the overall health of people receiving haemodialysis [–]. Depression is associated with decreased quality of life and increased morbidity [] and is an independent predictor of mortality, in part due to the impact that depression has on adherence to treatment []. People experiencing depression are less likely to be adherent to their treatment regimen [], increasing their risk of hospitalisation, morbidity and death []. Therefore, the issue of depression must be addressed amongst people receiving haemodialysis, to improve long-term outcomes for these patients, their families and carers and reduce the economic burden on the health service. Improving mental health support for people receiving haemodialysis has been identified as a priority by Kidney Care UK’s Psychosocial Health – A Manifesto for Action []. Currently, there is limited evidence on the effectiveness of antidepressant medication amongst people receiving haemodialysis [], in part because of the difficulties in trial design and the adverse events associated with medication [,–]. Cognitive behavioural therapy (CBT), another evidence-based treatment for depression, appears to be more effective at reducing symptoms of depression among people with kidney disease [,]. However, issues surrounding long-term implementation in practice, such as the need for a trained clinical psychologist to deliver the intervention [], the requirement to attend separate appointments (either in-person, online, or over the phone) [,], raise concerns about feasibility when resources are significantly limited, and patients already face a substantial treatment burden [,].